Boston, April 29, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leader in hybrid care enablement, today announced the release of its 2024 Corporate Responsibility Report, which details the company’s latest progress across environmental, social, and governance (ESG) topics and highlights Amwell’s growing positive impact on key stakeholders and the communities it serves.
“Corporate responsibility is fundamental to our mission to transform healthcare, which is facing a worsening environmental footprint, challenging social standards, and an increase in complex regulations,” said Ido Schoenberg, M.D., chairman and co-CEO of Amwell. “Our unique position at the center of a powerful and expanding network of health system and health plan clients provides us with a significant opportunity to embed responsible practices into our own business and help drive transformation across the industry to deliver measurable benefits. We’re proud to share these results and remain committed to continuous improvement.”
Amwell’s Corporate Responsibility Report examines the company’s business through an ESG lens across three key pillars: people, products, and operations. Since Amwell released its inaugural report in 2022, the company has made significant progress toward its goals.
Highlights from this year’s report include:
To read the full report, please visit Amwell Corporate Responsibility Report.
About Amwell
Amwell is a leading hybrid care enablement platform in the United States and globally, connecting and enabling providers, payers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that hybrid care delivery will transform healthcare. We offer a single, comprehensive platform to support all digital health needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With nearly two decades of experience, Amwell powers the digital care of more than 50 health plans, which collectively represent more than 100 million covered lives, and many of the nation’s largest health systems. For more information, please visit https://business.amwell.com/.
©2024 American Well Corporation. All rights reserved. Amwell®, SilverCloud®, ConvergeTM, CarepointTM and the Amwell Logo are registered trademarks or trademarks of American Well Corporation.
[1] Click here to access the source.
[2] Culture Amp: Technology, Science, Research North America, January 2024
Last Trade: | US$7.87 |
Daily Change: | 0.03 0.38 |
Daily Volume: | 77,920 |
Market Cap: | US$107.580M |
December 18, 2024 October 30, 2024 October 08, 2024 July 31, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB